𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: A phase II study

✍ Scribed by Peeter Padrik; Krista Leppik; Andrus Arak

Book ID
116955541
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
76 KB
Volume
22
Category
Article
ISSN
1078-1439

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Recombinant interferon alfa-2a in advanc
Recombinant interferon alfa-2a in advanced malignant melanoma. a phase i-ii study in combination with dtic
✍ G. R. C. McLeod; D. B. Thomson; P. Hersey πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 French βš– 384 KB

There is a rising incidence of malignant melanoma world-wide and, despite major improvements in i t s early diagnosis and treatment, the 10-year death rate remains at 20-25%. Evidence that the immune system has a role in the control of melanoma growth has encouraged immunological intervention. The r

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; FrΓ©dΓ©ric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p